Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

540 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Antiretrovirals and Weight Change: Weighing the Evidence.
Wohl DA, Koethe JR, Sax PE, McComsey GA, Kuritzkes DR, Moyle G, Kaplan L, van Wyk J, Campo RE, Cohen C. Wohl DA, et al. Among authors: van wyk j. Clin Infect Dis. 2024 Apr 12:ciae191. doi: 10.1093/cid/ciae191. Online ahead of print. Clin Infect Dis. 2024. PMID: 38606799
Weight changes and adverse pregnancy outcomes with dolutegravir- and tenofovir alafenamide fumarate-containing antiretroviral treatment regimens during pregnancy and postpartum.
Hoffman RM, Brummel S, Ziemba L, Chinula L, McCarthy K, Fairlie L, Jean-Philippe P, Chakhtoura N, Johnston B, Krotje C, Nematadzira TG, Nakayiwa F, Ndyanabangi V, Hanley S, Theron G, Violari A, João E, Correa Junior MD, Hofer CB, Navanukroh O, Aurpibul L, Nevrekar N, Zash R, Shapiro R, Stringer JSA, Currier JS, Sax P, Lockman S; IMPAACT 2010/VESTED Study Team. Hoffman RM, et al. Clin Infect Dis. 2024 Jan 5:ciae001. doi: 10.1093/cid/ciae001. Online ahead of print. Clin Infect Dis. 2024. PMID: 38180851
Asian participants' experience in phase 3/3b studies of long-acting cabotegravir and rilpivirine: Efficacy, safety, pharmacokinetic, and virological outcomes through week 96.
Oka S, Holohan V, Shirasaka T, Choi JY, Kim YS, Chamay N, Patel P, Polli JW, Ford SL, Crauwels H, Garside L, D'Amico R, Latham C, van Solingen-Ristea R, Baugh B, van Wyk J. Oka S, et al. Among authors: van wyk j. HIV Med. 2024 Mar;25(3):381-390. doi: 10.1111/hiv.13588. Epub 2023 Dec 26. HIV Med. 2024. PMID: 38147871
Efficacy, safety, and pharmacokinetics by BMI category in Phase 3/3b cabotegravir + rilpivirine long-acting trials.
Elliot E, Polli JW, Patel P, Garside L, Grove R, Barnett V, Roberts J, Byrapuneni S, Crauwels H, Ford SL, Van Solingen-Ristea R, Birmingham E, D'Amico R, Baugh B, van Wyk J. Elliot E, et al. Among authors: van wyk j. J Infect Dis. 2023 Dec 22:jiad580. doi: 10.1093/infdis/jiad580. Online ahead of print. J Infect Dis. 2023. PMID: 38134313
Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirine.
Patel P, Teichner P, Elliot E, Boffito M, Murray M, Polli JW, Baker M, Ford SL, Han K, Russu A, Crauwels H, D'Amico RD, Spreen WR, van Wyk J. Patel P, et al. Among authors: van wyk j. Ther Adv Infect Dis. 2023 Dec 13;10:20499361231214626. doi: 10.1177/20499361231214626. eCollection 2023 Jan-Dec. Ther Adv Infect Dis. 2023. PMID: 38107552 Free PMC article. Review.
540 results